90,034 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Acquired by Virtu Financial LLC

Virtu Financial LLC purchased a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 90,034 shares of the biotechnology company's stock, valued at approximately $967,000. Virtu Financial LLC owned about 0.11% of Anavex Life Sciences at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in AVXL. Berkshire Money Management Inc. acquired a new position in Anavex Life Sciences during the fourth quarter worth $107,000. Fiduciary Alliance LLC acquired a new position in Anavex Life Sciences during the 4th quarter worth about $119,000. D.A. Davidson & CO. purchased a new position in Anavex Life Sciences during the 4th quarter valued at about $122,000. Orion Capital Management LLC grew its position in Anavex Life Sciences by 666.7% in the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock valued at $65,000 after acquiring an additional 10,000 shares in the last quarter. Finally, PVG Asset Management Corp acquired a new stake in shares of Anavex Life Sciences during the third quarter worth about $74,000. Hedge funds and other institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Stock Performance

AVXL stock traded up $0.18 during mid-day trading on Thursday, reaching $9.54. The company had a trading volume of 1,015,448 shares, compared to its average volume of 1,233,720. The firm has a fifty day simple moving average of $9.03 and a 200 day simple moving average of $8.25. The company has a market capitalization of $811.51 million, a price-to-earnings ratio of -17.35 and a beta of 0.94. Anavex Life Sciences Corp. has a fifty-two week low of $3.25 and a fifty-two week high of $14.44.

Remove Ads

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. As a group, analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on AVXL shares. HC Wainwright restated a "buy" rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a report on Tuesday, February 18th. D. Boral Capital reissued a "buy" rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.